Search Results

Imagine Pharma, a biotech company focused on advancing the commercialization of its novel IMG-1 polypeptide in Oral Delivery, Therapeutics, and Regenerative Medicine, announced that the West Virginia University Health System, which operates under the brand WVU Medicine, has awarded a contract to the Company to provide human clinical islet isolation services for patients undergoing a total pancreatectomy and autologous islet cell transplant.

Imagine Pharma announced today that it has successfully completed more than 32 clinical islet cell isolation procedures for several leading hospital systems across the United States, including the Cincinnati Children’s Hospital Medical Center.

Verasonics, Inc. and French ultrasound equipment manufacturer SuperSonic Imagine, S.A. have reached an agreement to settle their ongoing litigation. SuperSonic Imagine has taken a license to certain Verasonics IP.

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65th Annual Meeting.

Imagine Pharma, a biotech company focused on furthering the commercialization opportunities related to its novel IMG-1 polypeptide, today announced that it has raised a $32.5 million Series A round, with an initial traunch of $10 million, bringing its total funding to date to $40 million.

CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”) and the Laboratory of Human Genetics of Infectious Diseases (the “Lab”) at Institut Imagine today announced a strategic research collaboration to improve health outcomes for rare disease patients by accelerating and de-risking drug discovery and clinical development.

Hologic, Inc. (Nasdaq : HOLX), a global leader in women’s health, and SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialized in ultrasound medical imaging, jointly announce today that Hologic Hub Ltd, a wholly-owned indirect subsidiary of Hologic, Inc., has acquired approximately 46% of SuperSonic Imagine shares, pursuant to a shares sale agreement entered into today.

LyGenesis, Inc. and Imagine Pharma , a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced new interim safety, biomarker, and survival data from cohorts 1-4 in the Imagine-1 clinical study.